Form N-8A T. Rowe Price Goldman

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-8A

 

NOTIFICATION OF REGISTRATION
FILED PURSUANT TO SECTION 8(a) OF THE
INVESTMENT COMPANY ACT OF 1940

 

The undersigned investment company hereby notifies the Securities and Exchange Commission that it registers under and pursuant to the provisions of Section 8(a) of the Investment Company Act of 1940 and in connection with such notification of registration submits the following information: 

Name: T. ROWE PRICE GOLDMAN SACHS ALL EQUITY ACCESS FUND

 

Address of Principal Business Office (No. & Street, City, State, Zip Code):

 

1307 Point Street

Baltimore, Maryland 21231

 

Telephone Number (including area code): (410) 345-2000

Name and address of agent for service of process:

 

David Oestreicher, Trustee

1307 Point Street, Baltimore, Maryland 21231

COPIES TO:

 

Gregory C. Davis, Esq.

Sarah Clinton, Esq.

Keith MacLeod, Esq.

Ropes & Gray LLP

800 Boylston Street

Prudential Tower

Boston, Massachusetts 02199

 

COPIES TO:

 

Margery K. Neale, Esq.

Elliot J. Gluck, Esq.

Michael A. DeNiro, Esq.

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019

 

Check Appropriate Box:

 

Registrant is filing a Registration Statement pursuant to Section 8(b) of the Investment Company Act of 1940 concurrently with the filing of Form N-8A:

 

YES ☒ NO ☐

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Investment Company Act of 1940, the Registrant has caused this notification of registration to be duly signed on its behalf in the City of BALTIMORE and State of MARYLAND on the 16th day of June, 2026.

 

T. ROWE PRICE GOLDMAN SACHS ALL EQUITY ACCESS FUND
(Name of Registrant)

 

By:	/s/ David Oestreicher
	David Oestreicher, Trustee

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
• Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Island Passage Exploration and Isina Resource Holdings Announce Land Access and Compensation Payments of 200,000 Kina made to customary landowners from work conducted on the EL02 Project Bougainville